08:23 AM EDT, 05/12/2025 (MT Newswires) -- Quantum BioPharma ( QNTM ) , up nearly 2% in U.S. pre-market trade, on Monday said dosing has been completed in 90-day oral toxicity and toxicokinetic studies for Lucid-21-302 (Lucid-MS) for Multiple Sclerosis (MS). These studies were commissioned to provide data to support an investigation new drug (IND) application with the U.S. FDA.

The company hopes to submit the IND application before the end of the year.

Quantum shares were last seen up US$0.18, to US$9.25, on the Canadian Securities Exchange.